Solu Therapeutics

Solu Therapeutics is a precision medicine company developing therapies to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company has obtained a patented license for the CyTaC (Cytotoxicity Targeting Chimera) platform and drug candidates from GlaxoSmithKline (GSK), unlocking antibody-refractory cell surface targets and enabling the development of next-generation drugs that leverage the vast small-molecule targeting space of biologics. Unique features of the CyTaC platform molecules include: (i) releasing novel tumor-associated antigens to eradicate cancer cells, (ii) depleting pathogenic immune cells, and (iii) extending the half-life of small-molecule antagonists and agonists.